trial · primary record
Risankizumab
Ulcerative Colitis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 120 |
| Primary completion | 2034-07 |
| Primary endpoint | PK Lead-In Cohort 1: Maximum Observed Serum Concentration (Cmax) |
| Registry ID | NCT07071519 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:13.769Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07071519
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.